Cancer Chemotherapy and Pharmacology

, Volume 15, Issue 2, pp 111–114 | Cite as

Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines

  • George P. Browman
  • Paula Spiegl
  • Lynda Booker
  • Andre Rosowsky
Original Articles Leucovorin, Antifolates
Received:
Accepted:

Summary

Leucovorin requirements for protection of the T cell line CCRF-CEM and the B cell line LAZ-007 against the cytotoxic effects of a variety of antifolates were studied. Differential leucovorin protection for DDMP-induced growth suppression occurred in the opposite direction to that for MTX, with CCRF-CEM requiring less leucovorin than LAZ-007 for equivalent protection. A pattern of differential protection from DDMP different from that of protection from MTX was also seen for the cell lines RAJI and MOLT-4. Differential leucovorin protection was observed for the chain-extended MTX analogue PT441. The degree of differential protection was similar to that seen for MTX, and transport studies showed that PT441 was a weak inhibitor of tritiated MTX uptake into CCRF-CEM cells. Differential leucovorin protection was observed for the lipophilic antifolate trimetrexate glucoronate (TMQ) but the degree of differential protection was smaller than that seen for PT441 or for MTX. Since TMQ is not transported into cells by the reduced folate system, while PT441 is a weak competitive inhibitor of [3H]MTX transport, and since neither is polyglutamylated, these results support the conclusion reached in previous experiments that differential leucovorin protection of MTX is unlikely to be a transport-related phenomenon and is not due to an effect on polyglutamylation. In addition, the different patterns of relative leucovorin requirements for DDMP and MTX protection suggest that differential metabolism or catabolism of leucovorin does not account for differential protection.

Keywords

Folate Leucovorin Transport Study Weak Inhibitor Lymphoid Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

MTX

methotrexate

HDMTX

high dose MTX

HPLC

high pressure liquid chromatography

[3H]dUrd

tritiated deoxyuridine

DDMP

2,4-diamino-5-(3′, 4′ dichlorophenyl)-6-methylpyrimidine

PT44

N-(4-amino-4-deoxy-N10-methylpteroyl)-L-α-aminoadipate

TMO

2,4-diamino-5-methyl-6-(3,4,5-trimethoxy-anilino)methyl) quinazoline

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bertino JR (1977) “Rescue” techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 4: 203–216Google Scholar
  2. 2.
    Browman GP (1982) Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines. Cancer Treat Rep 66: 2051–2059Google Scholar
  3. 3.
    Browman GP, Calvert AH, Taylor GA, Hart GI, Harrap KR (1980) The intracellular mechanism of action of metoprine (DDMP). Eur J Cancer 16:1547–1554Google Scholar
  4. 4.
    Browman GP, Hackett T, Booker L, Spiegl P, Muto R (1983) Differential folinic acid protection from methatrexate in human lymphoblastoid cell lines. Proc Am Assoc Cancer Res 24: 275Google Scholar
  5. 5.
    Browman GP, Booker L, Spiegl P (1985) Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate. Cancer Chemother Pharmacol 15: 105–110Google Scholar
  6. 6.
    Curt GA, Carney DN, Cowan KH, Jolivet J, Bailey BD, Drake JC, Kao-Shan CS, Minna JD, Chabner BA (1983) Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 1983; 308: 199–202Google Scholar
  7. 7.
    DeConti RC, Schoenfeld D (1981) A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 48:1061–1072Google Scholar
  8. 8.
    Diddens H, Niethammer D, Jackson RC (1983) Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43: 5286–5292Google Scholar
  9. 9.
    Fry DW, Yalowich JC, Goldman ID (1982) Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high-pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 257: 1890–1896Google Scholar
  10. 10.
    Fry DW, Anderson LA, Borst M, Goldman ID (1983) Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 43: 1087–1092Google Scholar
  11. 11.
    Goldin A, Venditti JM, Kline I, Mantel N (1966) Eradication of leukemia cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 212: 1548–1550Google Scholar
  12. 12.
    Moran RG, Rosowsky A, Coleman P, Forsch R, Chan K (1983) Substrate specificity of mouse liver folate polyglutamate synthetase. Proc Am Assoc Cancer Res 24: 279Google Scholar
  13. 13.
    Rosowsky A, Lazarus H, Yuan GC, Beltz WR, Mangini L, Abelson HT, Modest EJ, Frei E (1980) Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts. Biochem Pharmacol 29: 648–652Google Scholar
  14. 14.
    Rosowsky A, Forsch R, Uren J, Wick M, Kumar AA, Freisheim JH (1983) Methotrexate analogues. 20. Replacement of glutamate by longer-chain amino diacids: effects on dihydrofolate reductase inhibition, cytotoxicity, and in vivo antitumor activity. J Med Chem 26: 1719–1724Google Scholar
  15. 15.
    Sirotnak FM, Donsbach RC, Dorick DM, Moccio DM (1976a) Tissue pharmacokinetics, inhibition of DNA synthesis, and tumor cell kill after high-dose methotrexate in murine tumor models. Cancer Res 36: 4672–4678Google Scholar
  16. 16.
    Sirotnak FM, Donsbach RC, Moccio DM, Dorick DM (1976b) Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model. Cancer Res 36: 4679–4686Google Scholar
  17. 17.
    Vogler WR, Jacobs J, Moffitt S, Velez-Garcia E, Goldsmith A, Johnson L, MacKay S (1979) Methotrexate therapy with or without citrovorum factor in carcinoma of the head and neck, breast, and colon. Cancer Clin Trials 2: 227–236Google Scholar
  18. 18.
    Woods RL, Fox RM, Tattersall MHN (1981) Methotrexate treatment of advanced head and neck cancers: a dose response evaluation. Br Med J 282: 600–602Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • George P. Browman
    • 1
    • 2
    • 3
  • Paula Spiegl
    • 1
    • 2
    • 3
  • Lynda Booker
    • 1
    • 2
    • 3
  • Andre Rosowsky
    • 4
  1. 1.Hamilton Regional CenterOntario Cancer FoundationHamilton
  2. 2.Department of MedicineMcMaster UniversityHamiltonUSA
  3. 3.Oncology Research GroupMcMaster UniversityHamiltonUSA
  4. 4.Division of Cancer PharmacologyDana Farber Cancer InstituteBostonUSA

Personalised recommendations